1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10, 2015.
http://globocan.iarc.fr
. Accessed 10 March 2015
2. Bénard F, Turcotte É. Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography. Breast Cancer Res. 2005;7:153–62.
3. Penuelas I, Dominguez-Prado I, Garcia-Velloso MJ, Marti-Climent JM, Rodriguez-Fraile M, Caicedo C, et al. PET tracers for clinical imaging of breast cancer. J Oncol. 2012;2012:1–9.
4. Palmedo H, Bender H, Grunwald F, Mallmann P, Zamora P, Krebs D, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m-methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med. 1997;24:1138–45.
5. Caveliers V, Everaert H, John CS, Lahoutte T, Bossuyt A. Sigma receptor scintigraphy with N-[2-(1′-piperidinyl)ethyl]-3-[123I]iodo- 4-methoxybenzamide of patients with suspected primary breast cancer: first clinical results. J Nucl Med. 2002;43:1647–9.